What are your top takeaways in Thoracic Cancers from ASCO 2023?

Always so hard to pick a top 3 as luckily each ASCO provides us with a broad spectrum of significant advances in our field but if pressed against the wall, I might pick below 3:

1. The first is a double dip choice I admit matching ADAURA with KN789. Of course, you need to be living in a cave not to be ...

1. ADAURA. At ASCO 2020, this phase III study showed that adjuvant osimertinib for resected EGFR mutant NSCLC improved DFS (dramatically), leading to its FDA approval. At ASCO 2023, we saw the overall survival benefit that had been alluded to in a press release. It surpassed most of our expectations w...

1. The ADAURA results were highly anticipated and showed a better-than-expected hazard ratio for overall survival with using osimertinib after surgery for patients with resected IB-III EGFR mutated lung cancer.
2. The KEYNOTE-789 showing no benefit with pembrolizumab added to platinum alimta also in pat...

KEYNOTE-671, looking at perioperative chemoimmunotherapy, and the analogous NEOTORCH were consequential, not so much in that they might usurp the current standard pre-operative regimen of chemotherapy-nivolumab (based on the CheckMate 816 trial), but in that, the data very closely mirrored what we s...

1. KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC LBA 100

The trial looks at the addition of pembrolizumab to neo-adjuvant chemotherapy in resectable stage II, I...